Equities analysts predict that Sarepta Therapeutics Inc (NASDAQ:SRPT) will post earnings per share of ($0.35) for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Sarepta Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.56). Sarepta Therapeutics reported earnings per share of ($1.58) during the same quarter last year, which would indicate a positive year over year growth rate of 77.8%. The company is expected to announce its next quarterly earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.96) to ($0.68). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.79) per share, with EPS estimates ranging from ($1.58) to $0.20. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The company had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same quarter last year, the business earned ($0.95) EPS.

A number of brokerages have issued reports on SRPT. Credit Suisse Group reaffirmed an “outperform” rating and set a $81.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Robert W. Baird reaffirmed a “buy” rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $55.00 price objective (up from $50.00) on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $64.14.

In related news, CEO Douglas S. Ingram bought 38,138 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at $22,035,078.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The disclosure for this sale can be found here. Insiders sold 28,167 shares of company stock valued at $1,497,619 over the last 90 days. 9.60% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. grew its stake in shares of Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Sarepta Therapeutics by 116.4% during the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 2,474 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 2,493 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $204,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth about $206,000. Institutional investors and hedge funds own 82.02% of the company’s stock.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $52.60 on Friday. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $57.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/16/0-35-earnings-per-share-expected-for-sarepta-therapeutics-inc-srpt-this-quarter.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.